Plant closure hits ProStrakan

first_img KCS-content “The potential Sancuso manufacturing issue could be a bump in the road but should be temporary.”The company posted earnings before interest, tax, depreciation and amortisation (ebitda) of £1.2m for the six months to the end of June, against a £4.3m loss a year earlier, on 23 per cent higher revenue of £45.4m.Aveva Drug Delivery Systems, the maker of Sancuso, which had sales of £4.6m in the period, halted manufacturing for 8-12 weeks following an inspection by America’s Food and Drug Administration (FDA), ProStrakan said.“It’s a fluid situation and we don’t quite know what the outcome will be,” Totten said. “We are working with the manufacturer and the FDA towards making sure there is either no or minimal disruption to product supply.”Sales of Abstral, a formulation of fentanyl, used to treat sudden bouts of severe pain in cancer patients, rose to £7.4m. Thursday 19 August 2010 8:35 pm whatsapp whatsapp Read This Next’A Quiet Place Part II’ Sets Pandemic Record in Debut WeekendFamily ProofHiking Gadgets: Amazon Deals Perfect For Your Next AdventureFamily ProofBack on the Rails for Summer New York to New Orleans, Savannah and MiamiFamily ProofIndian Spiced Vegetable Nuggets: Recipes Worth CookingFamily ProofAmazon roars for MGM’s lion, paying $8.45 billion for studio behind JamesFamily ProofTortilla Mango Cups: Recipes Worth CookingFamily ProofYoga for Beginners: 3 Different Types of Yoga You Should TryFamily ProofWhat to Know About ‘Loki’ Ahead of Disney+ Premier on June 9Family ProofCheese Crostini: Delicious Recipes Worth CookingFamily Proofcenter_img Plant closure hits ProStrakan Tags: NULL HIGHER distribution costs and a potential manufacturing problem with an anti-nausea patch overshadowed ProStrakan’s first core profit yesterday, which rose on higher sales of drugs for cancer pain and age-related diseases.Shares in the pharmaceutical firm closed down 7.5 per cent at 74p, after an inspection forced it to halt production at the manufacturing plant for its Sancuso anti-nausea patch.Numis analysts also said distribution costs rose five per cent in the period, and that higher operating costs would continue.“With today’s confirmation of the excellent drive in sales, our downgrade on future operating expenditure is disappointing,” they said in a note. Show Comments ▼ Sharelast_img read more